



## From Bench to Bedside: Expanding the Scope of Thioredoxin Reductase Inhibitors as Promising Therapeutics for Tumors, Inflammatory Disorders, and Infectious Diseases

Guest Editors:

**Dr. Jianqiang Xu**

School of Life and  
Pharmaceutical Sciences, Dalian  
University of Technology, Panjin  
Campus, Panjin 124221, China

**Prof. Dr. Jun Lu**

Key Laboratory of Luminescence  
Analysis and Molecular Sensing,  
Ministry of Education (Southwest  
University), College of  
Pharmaceutical Sciences,  
Southwest University, Chongqing  
400715, China

Deadline for manuscript  
submissions:

**20 May 2024**

### Message from the Guest Editors

This Special Issue aims to select all in-depth studies that focus on expanding the understanding of current druggable structures, enhancing the synergic effects of combined medication, improving pharmacological function, and decreasing toxicological side-effects. These studies on druggable compounds or components include research on natural herb extracts, noble-metal complexes, or antioxidants for pharmaceutical application, and involving free radical research, redox biology, and tumor microenvironment regulation, are hereby very warmly welcome.

The investigation of small molecule inhibitors and druggable components is not limited to the aforementioned natural resources, clinical drugs, or known structures, but could also be extended to creative chemicals, dyes, pigments, probes, nutrients, and biological trace elements. The purpose of this Special Issue is to call for all pharmaceutical and biotechnological opinions/studies on novel molecules/structures targeting cellular thioredoxin reductase, intended for clinical application in the effective therapy of human cancer, inflammations, and infectious diseases.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)